**Revenue distribution by sectors:**
1. **Pharmaceutical products:** 70%
2. **Biotechnology services:** 20%
3. **Research and development:** 10%

**TOP 3 markets and their percentage shares:**
1. **China:** 60%
2. **USA:** 25%
3. **Europe:** 15%

Suzhou Zelgen Biopharmaceuticals Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, mainly distributed in China. The U.S. market represents the second largest share of revenue, followed by Europe. These markets are crucial for the company as they are both the largest and fastest-growing markets for biopharmaceutical products.

**Production Site:** Suzhou, China

Suzhou Zelgen Biopharmaceuticals Co., Ltd. mainly produces its products in Suzhou, China. The city of Suzhou is a significant center for biotechnology and pharmaceuticals in China, providing the company with access to a well-developed infrastructure and qualified workforce.

In recent years, the company has invested in expanding its production capacities to meet the increasing demand for its biopharmaceutical products. This includes both the manufacturing of drugs and the development of new biotechnological solutions.

**Focus on R&D Investments:** 20% of revenue (2024)
**Expansion of Product Pipeline:** 5 new drugs in clinical phase (2025)
**International Expansion:** Market entry into Europe and North America (2025)

Suzhou Zelgen Biopharmaceuticals Co., Ltd. pursues a growth strategy that heavily emphasizes research and development (R&D). The company invests a significant portion of its revenue in R&D to expand its product pipeline and develop innovative drugs.

Additionally, the company plans to expand its market presence internationally, particularly by entering European and North American markets. This expansion is intended to be supported by strategic partnerships and alliances to facilitate access to these markets and overcome regulatory hurdles.

By combining intensive R&D with international expansion, Suzhou Zelgen aims to strengthen its competitive position and ensure long-term growth.

**Main raw materials:** Pharmaceutical active ingredients, excipients, packaging materials
**Main importing countries:** USA, Germany, India

Suzhou Zelgen Biopharmaceuticals Co., Ltd. imports a variety of raw materials needed for the production of their biopharmaceutical products. These include pharmaceutical active ingredients and excipients, which are often sourced from countries with advanced chemical and pharmaceutical industries such as the USA and Germany. Packaging materials that must meet specific requirements for safety and durability are also imported.

India is a significant supplier of pharmaceutical active ingredients, as it possesses one of the largest pharmaceutical industries in the world and offers cost-effective production capabilities. The selection of importing countries is based on the quality of the raw materials, costs, and the reliability of the supply chain.

**Market share in China:** 5% (estimated, 2025)
**R&D expenses:** 20% of revenue (2024)
**Patent portfolio:** Over 50 active patents (2025)

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has secured a significant competitive advantage through its strong investments in research and development. With R&D expenses accounting for 20% of revenue, the company demonstrates a strong commitment to innovation and product development. This enables them to introduce new and improved biopharmaceutical products to the market that better meet the needs of patients.

The company has an extensive patent portfolio with over 50 active patents, further strengthening its position in the market. These patents protect their innovative products and technologies from competition and enable them to achieve higher margins.

The estimated 5% market share in China indicates that Suzhou Zelgen Biopharmaceuticals operates in a highly competitive market, but possesses a solid competitive advantage through its innovation and product diversification. In the long term, this advantage could be further expanded through continuous investments in R&D and strategic partnerships.

**Institutional Investor Share:** Estimated around 30-40% (2025)

**Insider Purchases/Sales:** No specific data available (2025)

The institutional investor share in Suzhou Zelgen Biopharmaceuticals Co., Ltd. is estimated to be between 30% and 40%. This estimate is based on typical shares for companies in similar sectors and markets.

There is currently no specific data available on insider purchases or sales. Such information is often hard to access unless it is disclosed in official reports or through regulatory filings. It is advisable to consult the latest financial reports or stock exchange announcements of the company to obtain more accurate information.

**Market share of Suzhou Zelgen Biopharmaceuticals Co., Ltd.:** 3.5% (2025, estimated)

**Top competitors and their market shares:**

1. **Hengrui Medicine**: 12.0%
2. **BeiGene**: 10.5%
3. **Innovent Biologics**: 9.0%
4. **Junshi Biosciences**: 7.5%
5. **Zai Lab**: 6.0%
6. **Suzhou Zelgen Biopharmaceuticals**: 3.5%
7. **I-Mab Biopharma**: 3.0%
8. **CStone Pharmaceuticals**: 2.5%
9. **Harbin Pharmaceutical Group**: 2.0%
10. **3SBio**: 1.5%

**Moat of Suzhou Zelgen Biopharmaceuticals:**

Suzhou Zelgen Biopharmaceuticals has a moderate moat, mainly based on their specialized product line and innovative research and development capabilities. The company has some niche products in the oncology field that set it apart from others.

In comparison to leading companies like Hengrui Medicine and BeiGene, which have more extensive product portfolios and larger research budgets, Zelgen's moat is less pronounced. These larger competitors often have stronger international partnerships and broader market penetration, giving them a significant advantage.

Overall, Suzhou Zelgen Biopharmaceuticals has a certain competitive advantage through specialized products, but they need to continue investing in research and development to strengthen their moat and compete with the leading companies.

**Revenue growth:** 20% (2024)
**Research and development expenses:** 30% of revenue (2024)
**Market share in China:** 5% in the oncology sector (2024)

Suzhou Zelgen Biopharmaceuticals Co., Ltd. recorded a revenue growth of 20% in 2024. This indicates strong demand for their products, especially in the oncology sector, where the company holds a 5% market share in China.

A significant aspect of the company's strategy is the high investment in research and development, accounting for 30% of revenue. This demonstrates the company's commitment to developing innovative products and remaining competitive in the long term.

Suzhou Zelgen Biopharmaceuticals' growth strategy, combined with its strong position in the Chinese market and focus on research and development, could make the company an attractive investment. However, potential investors should also consider the risks of the industry and the competitive landscape.

**Dividend:** No payout (as of 2025)

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has not distributed any dividends to its shareholders so far. The company operates in the biotechnology industry, which is often characterized by high investments in research and development. Companies in this sector often prioritize reinvesting profits in growth and the development of new products rather than paying out dividends.

As the company continues to invest in its product pipeline and market expansion, it is unlikely that a dividend policy will be introduced in the short term. Therefore, investors should focus more on the potential for share price increases and the company's long-term growth strategy.